Table 3.
Dose-response Tertiapin-Q experiment in dorsal and ventral CA1 neurons (related to Fig. 2)
| 0.03 μM Tertiapin-Q |
0.3 μM Tertiapin-Q |
2 μM Tertiapin-Q |
||||
|---|---|---|---|---|---|---|
| Baseline | Tertiapin | Baseline | Tertiapin | Baseline | Tertiapin | |
| Dorsal CA1 | ||||||
| Vm, mV | −69.9 ± 1.0 (n = 7) | −67.8 ± 1.1 (n = 7) | −69.0 ± 0.5 (n = 7) | −64.4 ± 0.5* (n = 7) | −69.4 ± 0.9 (n = 6) | −65.4 ± 0.9* (n = 6) |
| Rin, MΩ | 60.2 ± 2.8 (n = 7) | 70.5 ± 3.5 (n = 7) | 62.9 ± 1.2 (n = 7) | 82.6 ± 2.2* (n = 7) | 64.5 ± 3.9 (n = 6) | 85.6 ± 4.5* (n = 6) |
| Ventral CA1 | ||||||
| Vm, mV | −65.3 ± 1.0 (n = 6) | −64.7 ± 1.4 (n = 6) | −64.9 ± 0.5 (n = 6) | −63.0 ± 0.7 (n = 6) | −64.1 ± 0.8 (n = 6) | −62.6 ± 0.9 (n = 6) |
| Rin, MΩ | 82.5 ± 4.8 (n = 6) | 87.2 ± 5.8 (n = 6) | 87.3 ± 3.0 (n = 6) | 95.8 ± 2.7 (n = 6) | 85.0 ± 4.8 (n = 6) | 89.1 ± 3.9 (n = 6) |
Statistically significant (
*
P < 0.0167, 1-way ANOVA with Bonferroni post hoc test compared with baseline).